OSE Immunotherapeutics SA
PAR:OSE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.2
10.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA
Total Current Liabilities
OSE Immunotherapeutics SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Current Liabilities
€17.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€102.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Current Liabilities
€49.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
32%
|
CAGR 10-Years
32%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€36.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€48.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Current Liabilities
€52.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Total Current Liabilities?
Total Current Liabilities
17.4m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Total Current Liabilities amounts to 17.4m EUR.
What is OSE Immunotherapeutics SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-3%
Over the last year, the Total Current Liabilities growth was -6%. The average annual Total Current Liabilities growth rates for OSE Immunotherapeutics SA have been -5% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
